BANU K ARUN to Risk Assessment
This is a "connection" page, showing publications BANU K ARUN has written about Risk Assessment.
Connection Strength
0.574
-
Clinical application of breast cancer risk assessment models. Future Oncol. 2010 Mar; 6(3):355-65.
Score: 0.145
-
Genetic risk assessment for breast and gynecological malignancies. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):1-5.
Score: 0.051
-
Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2012 May; 133(1):347-55.
Score: 0.041
-
Clinical assessment of breast cancer risk based on family history. J Natl Compr Canc Netw. 2010 Oct; 8(10):1148-55.
Score: 0.038
-
Building a predictive breast cancer risk model. AMIA Annu Symp Proc. 2007 Oct 11; 995.
Score: 0.031
-
Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812. JNCI Cancer Spectr. 2024 Jul 01; 8(4).
Score: 0.024
-
Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. J Clin Oncol. 2024 Jun 20; 42(18):2186-2195.
Score: 0.024
-
Ductal lavage and risk assessment of breast cancer. Oncologist. 2004; 9(6):599-605.
Score: 0.024
-
Personalized Breast Cancer Risk Assessment: Incorporation of Genetic and High-Risk Factorson Breast Cancer Risk and Management. Chirurgia (Bucur). 2021 12; 116(5 Suppl):S22-S34.
Score: 0.020
-
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genet Epidemiol. 2020 07; 44(5):442-468.
Score: 0.018
-
Validation of a personalized risk prediction model for contralateral breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):415-423.
Score: 0.016
-
Association analysis identifies 65 new breast cancer risk loci. Nature. 2017 11 02; 551(7678):92-94.
Score: 0.015
-
Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 2016 Dec 06; 7(49):80465-80481.
Score: 0.014
-
A two-stage approach to genetic risk assessment in primary care. Breast Cancer Res Treat. 2016 Jan; 155(2):375-83.
Score: 0.014
-
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol. 2015 Nov 01; 33(31):3660-7.
Score: 0.013
-
BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist. 2015 Jun; 20(6):593-7.
Score: 0.013
-
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015 Jan 15; 121(2):269-75.
Score: 0.012
-
Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother. 2012 Feb; 13(3):325-31.
Score: 0.010
-
Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer. 2011 Dec; 10(4):673-9.
Score: 0.010
-
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Nov; 124(2):441-51.
Score: 0.009
-
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14.
Score: 0.008
-
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
Score: 0.008
-
Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006 Jan 20; 24(3):354-60.
Score: 0.007
-
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
Score: 0.007